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Original article
Mixed methods study of a new model of care for
chronic disease: co-design and sustainable
implementation of group consultations into clinical
practice
Michele Russell-Westhead1,2, Nicola O’Brien1,2, Iain Goff3, Elizabeth Coulson3,
Jess Pape3 and Fraser Birrell1,3
Abstract
Objectives. Group consultations are used for chronic conditions, such as inflammatory arthritis, but
evidence of efficacy for treatment to target or achieving tight control is lacking. Our aim was to estab-
lish whether group consultation is a sustainable, co-designed routine care option and to explore fac-
tors supporting spread.
Methods. The study used mixed methods, observational process/outcome data, plus qualitative ex-
ploration of enabling themes. It was set in two community hospitals, in 2008–19, with a third hospital
from 2016, and was triangulated with primary care qualitative data. There was a total of 3363 arthritis
patient attendances at 183 clinics during 2008–19. The early arthritis cohort comprised 46 patients, fol-
lowed monthly until the treatment target was achieved, during 2016–19. Focus groups included 15 ar-
thritis and 11 osteoporosis group attendees. Intervention was a 2 h group consultation, attended
monthly for early/active disease and annually for stable disease. Measurements included attendance,
DAS, satisfaction and enabling themes.
Results. There was a mean number of 18.4 patients per clinic (n¼ 16, 2010–15; n¼ 18, 2016; n¼ 20,
2017; n¼ 23, 2018–19). Forty per cent (1161/2874) of patients with DAS data reached low disease ac-
tivity (DAS< 3.2) or remission (DAS< 2.6). Forty-six early arthritis patients followed monthly until they
achieved remission responded even better: 50% remission; and 89% low disease activity/remission by
6 months. Qualitative analysis derived five main enabling themes (efficiency, empathy, education, en-
gagement and empowerment) and five promotors to translate these themes into practice (prioritization,
personalization, participation, personality and pedagogy). Limitations included the prospectively col-
lected observational data and pragmatic design susceptible to bias.
Conclusion. Co-designed group consultations can be sustainable, clinically effective and efficient for
monthly review of early active disease and annual review of stable disease. Promoting factors may
support effective training for chronic disease group consultations.
Key words: quality of health care, chronic disease, pain assessment and management, patients, outcomes,
group consultations
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Introduction
Inflammatory arthritis encompasses a group of chronic,
painful and disabling conditions, the most common form
of which, RA, affects 4.2% of the US adult population
[1]. The total cost to the US economy is estimated at
$19.3 billion per annum [2]. Early diagnosis and aggres-
sive management have been proved to reduce morbidity
and prevent disability. The UK National Institute for
Health and Care Excellence (NICE) clinical guidelines for
patients with RA, the commonest form of inflammatory
arthritis (NG100) [3] are consistent with the ACR guid-
ance [4] for a tight control strategy, with monthly review
and treating to target [5] (inspired by diabetes care).
These two major concepts have large service implica-
tions: regular, preferably monthly, review of patients with
poor disease prognosis until the achievement of an
agreed treatment target; and annual review of patients
who have stable disease. In practice, rheumatologists
also manage PsA using the same treatment strategies,
and the evidence base to support this is now robust
[6, 7]. In the current UK health economic climate, as in
other countries around the world, many units lack the
clinical capacity to deliver this enhanced workload
model to manage inflammatory arthritis; therefore, other
models of care need to be considered.
Demand to care for those with long-term conditions is
high and set to rise exponentially as the population
ages. This is a universal issue worldwide; caregivers
are overwhelmed [8]. The current consultation model
provides little time to support people in taking control
and self-managing their health. Research suggests
that people retain 20–60% of the information (forgetting
40–80%) in one-to-one consultations [9]. Furthermore,
staff well-being is affected by current practice, with
primary care clinicians reporting unprecedented levels of
stress and burnout. In hospital settings, the link between
burnout and compromised patient safety is well estab-
lished and likely also to apply in primary care [8]. Under
the current consultation model, no one is getting what
they need to keep well. Scaling up group consultations,
an innovation already established in other countries,
could be part of the solution that simultaneously creates
time to care and improves patient activation and staff–
patient life outcomes [8].
Group consultations are a way of delivering specialist-
led care in groups, rather than individual consultations,
that generally focus on clinical management and advice,
in addition to patient education and peer support. They
have the potential for effective health care within these
resource constraints, but the approach is not yet wide-
spread outside the USA. First described in 1974 as clus-
ter visits, group consultations have been widely used in
the USA, largely for people with long-term conditions,
and usually take place in hospital outpatient services
but may also feature in community-based clinics or pol-
yclinics. They have been used by a large health mainte-
nance organization, Kaiser Permanente, to see patients
in primary care or with a single problem in secondary
care. Group consultation models take a variety of
forms, such as shared medical appointments, physical
shared medical appointments, self-management, drop-
in group medical appointments, group visits and
co-operative health-care clinics, and this was flagged
as one area to benefit from a systems approach to im-
plementation [10]. They have been shown to be more
effective than usual care for antenatal care, diabetes
and hypertension [10] and for multiple coexistent con-
ditions [11]. There is also some evidence of potential
cost savings and improved patient satisfaction with
varying degrees of effect in relationship to empower-
ment, shared experience and increase in knowledge;
a study comparing patient group interventions with tra-
ditional one-to-one consultations revealed that patients
felt they had better access to care and were more
satisfied overall with the care that they received in the
group clinic setting [12].
If group consultations provide good clinical outcomes,
are popular with patients and cost-effective, why are
they not routinely used for patients with long-term medi-
cal conditions in the overburdened National Health
Service (NHS)? The literature argues that extremely
complex clinical and organizational settings present
substantial barriers to implementation of any health-care
innovation, ‘leading to model modification, incomplete
implementation, or failure to successfully embed inter-
ventions within health care systems’ [13]. A US study of
pre-natal group clinics reported bureaucratic organiza-
tional structures, lack of buy-in and financial resources,
and staff who were overwhelmed by the model’s chal-
lenges as reasons why clinics fail [14]. Group clinics are
a substantial paradigm shift from individual one-to-one
consultant-led care, which has significant resource, op-
erational and cultural implications. With the majority of
evidence for group interventions based in the USA and
a perceived dearth of evidence elsewhere, it has been
difficult to ascertain whether the model works in the
Key messages
. A group consultation model co-designed with patients delivered excellent patient outcomes and was sustainable
at scale.
. A group consultation model can be used to implement group consultations widely in different health-care settings.
. Key enabling factors: efficiency, empathy, education, engagement and empowerment.
. Active ingredients: prioritization, personalization, participation, pedagogy and personality.
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NHS and other socialized health-care systems. In order
to roll out group consultations, a recent editorial by
Ramdas and Darzi [15] provided four reasons for the slow
uptake and suggested conditions that need to be present
to improve this. Expressed as crucial enablers for group
consultations to be embedded as a service delivery
standard, these are as follows: collecting rigorous scien-
tific evidence; discovering easy ways to pilot and refine
approaches before fully adopting them; regulatory change
or incentives supporting the use of such models; and
relevant patient and clinician education.
The aim of the present study was to confirm the feasi-
bility and sustainability of the group consultation model
as an alternative to one-to-one appointments in the
NHS. We demonstrate the application of group clinics in
rheumatology, developed and implemented within a
10-year longitudinal, mixed methods study and adapted
for a range of settings and long-term conditions.
The objectives were as follows: to articulate the co-
design process used in the development and delivery;
to demonstrate that key disease outcome data for in-
flammatory arthritis (as a prototypical chronic condition)
can be collected from a group consultation model and
that outcomes and efficiency compare favourably with
usual care; to identify enabling themes and promoting
factors for the success, acceptability and translatability
of the model; and to make recommendations for the
rolling out and scaling up of group clinics.
The relevance of this paper to the group consultation
evidence base is that it articulates the process of co-
design of the group clinic model with patients and key
stakeholders. The process covers piloting and imple-
menting an idea, becoming an embedded and sustain-
able model across an entire service, and adapting
the model to suit a range of health-care settings and pa-
tient populations in an iterative cycle of feedback and
refinement. Although this process has undoubtedly been
followed in the USA, where, for example, the Cleveland
Clinic has embedded group consultations, delivering
100 000 shared medical appointments [16], the present
study provides evidence of the generalizability to other
countries and socialized health systems. The recent
editorial on group consultations [8] provoked intense
debate about the importance of patient involvement in
development and evaluation [17], and there has been
further recent national media attention, making this
front-page news. The aim of this study was to contribute
evidence that patient co-design facilitates the adoption
and sustainability of group clinics in a wide range of
long-term conditions in the UK, in addition to informing
the international evidence base.
Methods
Study design
This is a 10-year longitudinal study detailing the devel-
opment of a group consultation model at Northumbria
Healthcare NHS Foundation Trust. Sustainable models
were derived and adapted from an original consultant-
led group clinic for both active early and stable inflam-
matory arthritis, which was subsequently operationalized
in a range of settings and chronic conditions (see
Fig. 1). We use a mixed methods approach, defined as
incorporating both quantitative and qualitative data (in this
case, a triangulation multilevel model) to collect key clinical
outcome and patient satisfaction data and involved
patients and key organizational stakeholders to help co-
design, evaluate and refine the model by identifying the
key enablers for successful implementation. An adapted
experience-based co-design model [18] was adopted, in
which patient feedback during clinics helped to inform the
clinic design. In health care, the term co-design refers to
patients and carers working in partnership with staff to im-
prove services [19]. The clinics were held in a community
hospital setting or in general practice.
Observational data (good for capturing process flow,
satisfaction and outcomes) were triangulated with obser-
vational and in-depth interview data (qualitative; good
for exploring complexity, including reasons for success)
from staff and patients attending a pharmacy-led osteo-
porosis group clinic in general practice [20] and patients
attending a homogeneous early arthritis multi-
professional group clinic. The qualitative data also re-
fined the approach for subsequent clinics.
Ethical approval was granted by Newcastle and North
Tyneside 1 Research Ethics Committee (REC approval
reference 10/H0906/88).
Patient involvement
Patient involvement in the group clinic has been integral
from the outset and at every stage, including develop-
ment, delivery and quality improvement (see figure 2 of
Jones et al. [10]). This has been articulated in a rapid re-
sponse to an editorial [21], including initial scepticism by
the patient representative working with the
Rheumatology team when the first pilots were proposed
in 2008, which was overcome by the experience of at-
tending in 2017. We hoped to show that with true, itera-
tive co-design, initial concerns may be overcome, and a
deep connection with the group clinic model can de-
velop. The patient voice directly informed development
the model, especially in response to challenges (see
Tables 1 and 2). The results have been used to refine
the model and have been disseminated to patients at
the group clinics. In addition, patient representatives
have been involved actively in contributing to grant sub-
missions and publications.
Clinical outcome data: methods, patients, sampling
and data analysis
The group consultation model with three distinct adapta-
tions over time is described here, to demonstrate how
the model is adaptable to different settings and chronic
conditions (see Fig. 1). The original consultant-led group
Group consultations in clinical practice
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FIG. 1 Group clinic co-design timeline (with patients and multidisciplinary team) and delivery
MDT: multidisciplinary team.
TABLE 1 Group clinic model adaptations to meet service and patient need
Osteoporosis group clinic:
pharmacist-led clinic
Group clinic: consultant-led
MDT clinic
Early arthritis group clinic:
consultant-led MDT clinic
Clinic administration Administration streamlined;
available ahead of clinic
Administration streamlined;
available ahead of clinic
Administration streamlined;
available ahead of clinic
Introduction Introduction and ground rules
(shared confidentiality; bal-
ancing contribution)
Introduction and ground rules
(shared confidentiality; bal-
ancing contribution)
Introduction and ground rules
(shared confidentiality; bal-
ancing contribution)
Education
and tools
FRAX score self-calculated Created an educational poster
(Supplementary Fig. S1, avail-
able at Rheumatology
Advances in Practice online)
HAQ self-completed
Educational posters
HAQ completed with nurse
Additional staff None; clinic facilitated by
pharmacist
Usually led by a single pharma-
cist, although pilot clinics had
a specialist nurse and/or ex-
pert consultant present for
model development and
training
MDT member (specialist nurse,
occupational therapist, phys-
iotherapist, podiatrist or phar-
macist, depending on
availability) delivers arthritis
education for 1 h
Clinic nurse
MDT member (6-monthly
rotation, including specialist
nurse, occupational therapist,
physiotherapist and podiatrist)
delivers arthritis education for
1 h
Clinic nurse/health-care
assistant
Investigations and
procedures
No blood tests required Clinic nurse organizes clinic and
undertakes clinical proce-
dures (e.g. i.m. CS injections
and blood tests, if needed)
Clinic nurse organizes clinic and
undertakes clinical proce-
dures (e.g. i.m. CS injections
and blood tests, if needed)
Location and
format
10 patients in a general
practice
12–32 patients in a group edu-
cation room in a community
hospital
14–20 patients in a group edu-
cation room in a community
hospital
Micro-consultations No parallel micro-consultations
Pharmacist-facilitated group
session covering osteoporo-
sis, fracture risk, lifestyle and
treatment
Consultant undertakes micro-
consultations: DAS, treatment
choices and provides infor-
mation leaflet (1–2 min per
patient)
Consultant undertakes parallel
micro-consultations: DAS,
treatment choices and pro-
vides information leaflet (4
min per patient)
Interactive
education
Question and answer session:
engaged in discussion, with
an opportunity to discuss
confidential issues after the
group session
Consultant delivers inflamma-
tory arthritis education based
on the concerns highlighted
by patients during micro-
consultation
Consultant leads open question
and answer session after
completion of micro- consul-
tations and a break
Prescriptions Offered prescription for alendr-
onate, calcium/vitamin D3.
Written information/health
promotion about
osteoporosis
Prescription for new drugs, con-
fidential concerns and joint
injections if required
Prescription for new drugs, con-
fidential concerns and joint
injections if required
(continued)
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clinic in 2008–2015 (observational and qualitative data;
model 1) forms the basis of best practice in group
clinics and has been constantly evaluated and improved
using the iterative co-design model as described above.
The three adaptations are as follows: (1) a pharmacist-
led osteoporosis group clinic (OPGC) in primary care
(qualitative comparison alongside randomized controlled
trial with 12-month follow-up) 2012–2014, following
multidisciplinary co-design (2009–2010); (2) a multi-disci-
plinary supported, consultant-led group clinic 2015–2019
(observational data); and (3) an early arthritis group clinic
(EAGC) 2016–2019 (observational data).
The primary clinical outcome data (model 1 and
adaptation 3 above) are derived from two community
hospitals serviced by a single rheumatology unit, con-
sisting of consecutive group clinics since piloting July–
September 2008, with routine implementation in May
2010 through to July 2019 (see Table 1). Early data were
derived from a consultant-led model, with later clinics
adopting a multi-professional approach in response to
patient requests. This is triangulated with data from a
multi-disciplinary team EAGC (adaptation 3 above; 46
unique patients attending monthly clinics) from July
2016 to October 2018. Data include attendance (for the
whole period), i.m. CS injection (collected since August
2012) and DAS [22] (DAS28; collected since November
2012), with categorization of patients as in remission
(DAS28< 2.6) or with low (DAS28< 3.2), moderate
(DAS28¼ 3.2–5.0) or high disease activity (DAS285.1).
Corresponding values for PsA were no swollen and ten-
der joints (remission) and one or two swollen and tender
joints (low disease activity).
Patient feedback on the content and structure of the
clinic was collected at the end of each session using a
co-designed, Trust-developed Rheumatology patient
experience survey, and the same survey was sent to
437 usual clinic patients, which was completed by 263
patients (60% response rate) for comparison. Similar
feedback was obtained from the EAGC in the set-up
phase (data not shown). Many group clinic sessions
were observed informally and two sessions formally by
a clinical education expert, who also undertook the
qualitative evaluation (see qualitative evaluation para-
graph below), to articulate the clinic structure properly,
assess patient engagement in the group situation and
identify good practice. These findings formed an
TABLE 1 Continued
Osteoporosis group clinic:
pharmacist-led clinic
Group clinic: consultant-led
MDT clinic
Early arthritis group clinic:
consultant-led MDT clinic
Target patients One-off clinic to manage those
at risk: invitation to review for
those who stop therapy
feasible
Early arthritis/flaring patients
attend monthly clinic until
disease is controlled. Stable
patients attend annually
Patients attend monthly clinic
until disease is controlled
Feedback Feedback sought and fed into
clinic improvement
Feedback sought and fed into
clinic improvement
Feedback sought and fed into
clinic improvement
MDT: multidisciplinary team.
TABLE 2 Problem solving with iterative co-design: identifying group clinic challenges and solutions
Problem Solution
Poor response to anonymous invitations (GC/EAGC/OPGC) Invitation at time of first clinic appointment/flare
Reticence for serial observed consultations (GC) Adoption of less threatening problem-oriented discussion and
micro-consultations
Patients waiting to book in for clinic (GC) Book patients in once seated in group clinic
Patients queuing for injections after clinic (GC) Offer injections during clinic
Patients requesting more education from MDT (GC) Rotating involvement of team members delivering education
concurrent with consultant micro-consultations
Patients missing out on education by having injections/
micro-consultation during education (GC/EAGC)
Recap patients on their return (GC)
Offer choice of injection after clinic/develop posters for core
content (IAGC)
Micro-consultations taking too long and too far
from group room (EAGC)
Clearer briefing on ground rules of purpose and alternate use of
two rooms, improving flow
Lack of interaction in early clinics (GC/EAGC) Rearrange seating into a circle to encourage interaction
Falling attendance when one consultant was
not seeing new patients; less discussion (EAGC)
Invite follow-up patients to attend (the new patients found this
very helpful)
Low attendance when clinic was split to
prevent overbooking, reducing the group effect (GC)
One group in larger venue; MDT education; option to depart
after micro-consultation
GC: group clinic; EAGC: early arthritis group clinic; MDT: multidisciplinary team; OPGC: osteoporosis group clinic.
Group consultations in clinical practice
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educational model to support staff training and develop-
ment of the approach.
Qualitative themes were triangulated with group clinic
feedback and both types of data from a pharmacy-led
osteoporosis clinic model (OPGC, variation 1 above; 75
patients and four clinics).
Qualitative evaluation: methods, patients, sampling
and data analysis
A pragmatic qualitative approach [23] was used to ex-
plore the experience of patients and ascertain barriers
and enablers to the spread of group consultations.
Focus group interviews were carried out between June
and August 2014 at two hospital sites by two research-
ers. Researcher A (M.R.-W.) is an educationalist with a
clinical health-care, medical education (including doctor-
ate) and policy background, and researcher B (F.R.) is a
rheumatology registrar. This mix of disciplinary, profes-
sional and research backgrounds was specifically cho-
sen to capture the nuances of the health-care and
education models used and the social science aspects
of patient experience. The participants were unknown to
both researchers.
Sampling
Fifteen group clinic attendees self-selected to be inter-
viewed after information about the research project was
sent out to all patients invited by mail to the clinics. This
was 62% of all patients seen in those sessions.
Reasons provided for non-participation in the study
were mainly time related. Fourteen were patients (12
women and 2 men) and one was a male relative
(Table 3). Informed consent was gained from the
patients by researcher B, and they were advised how
the data would be used and that they could withdraw
from the study at any point and that this would affect
their care in no way. All had attended previous one-to-
one clinics and at least one group clinic. The focus
groups took place immediately after the group clinic and
lasted an average of 1 h.
Data collection
Researcher A facilitated the focus group using a semi-
structured interview guide, with introductory remarks
about the purpose of the study, prompts and some
broad opening questions to start the conversation, such
as, ‘Tell us about your experience of attending the group
clinics’, ‘How does it differ from the one-to-one consul-
tation?’, ‘What do you like about it/what works well for
you?’, and ‘Is there anything that could be improved
upon?’. Prompts and probes were used by both
researchers to elicit rich data from the patients. The
interviews were recorded digitally and transcribed ver-
batim by researcher B, who also made field notes to
check findings and act as an aide memoire to the focus
group proceedings (for example, non-verbal cues).
Transcriptions and interview notes were uploaded into
QSR’s NVivo 9 qualitative data analysis software (QSR
International, Melbourne).
Data analysis
The focus group transcripts were analysed by
researcher A using thematic analysis [24] and constant
comparison techniques, which are methods widely used
for identifying, analysing and reporting patterns (themes)
within data. The coding process was started by concep-
tualizing the meaning given by the patients by reading
and re-reading the transcripts. Comments with similar
meanings were clustered and give a nominal heading.
Coded extracts and sub-codes were then put together
and examined. Given that all patients had experience of
both group clinics and one-to-one consultations, data
were analysed together, and responses for each group
were compared within each theme to identify similarities
and differences between groups and to develop under-
standings with practical implications. Data saturation
was reached when no new themes were emerging. Both
researchers then re-read the data obtained through this
system of organization and refined the data by discus-
sing the codes and the themes one by one to reach a
consensus on the patient experience of group clinics
described by the patients themselves. The results were
triangulated with qualitative data from patients in the os-
teoporosis group clinics [11 white female patients, mean
age 70 (range 62–88) years]. In addition, the consultant
rheumatologist leading this initiative was also inter-
viewed by researcher B to provide historical insight into
the development of group clinics and to examine his
perceptions of the differences between the original
consultant-led model and the pharmacist-led osteoporo-
sis variant.
This was then written up by researcher A using
vignettes from the all the data, the patients’ and consul-
tant’s experiences, to illustrate the themes.
TABLE 3 Patient focus interviewees: inflammatory arthritis
group clinics
Hospital A Hospital B
AA White female 70–79
years old
BA White female 80–89 years
old
AB White male 70–79
years old
BB White female 60–69 years
old
AC White male 60–69
years old
BC White female 70–79 years
old
AD White female 50–59
years old
BD White female 60–69 years
old
AE White female 50–59
years old
BE White female 60–69 years
old
AF White female 60–69
years old
BFWhite male
AG White female 50–59
years old
(BE’s husband, not RA patient
himself)
AH White female 70–79
years old
BG White female 70–79 years
old
Michele Russell-Westhead et al.
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Results
Clinical outcome data
From 2010 to 2019, there were 3363 patient attendan-
ces over 183 mixed clinics, giving a mean of 18.4
patients attended each 2 h mixed clinic. Mean atten-
dance varied over time, with the pilots in 2008 having 10
(8 and 12) patients; 2010–2015, 15 (range 10–24)
patients; 2016, 18 (range 12–26) patients; 2017, 20
(range 14–32) patients; and 2018–19, 23 patients (range
17–28), suggesting that efficiency improved over time,
with no reduction in satisfaction (data not shown). Forty
per cent (1161/2874) patient attendances with DAS data
reached low disease activity or remission.
Administration of i.m. CS was more frequent for the later
clinics than for the pilots (where 5/20 received it, i.e.
25%): given in 1596 (55%) of 2904 patients where injec-
tion data were collected routinely. The more recently
established homogeneous early arthritis cohort (EAGC;
46 patients) showed even more impressive response: re-
mission was achieved in 23 out of 46 patients where full
data were available (50%) by 6 months, with another 18
patients having low disease activity (39%; giving 89% of
the total with low disease activity). Of the five remaining
patients who had moderate (n¼ 3) or high disease
activity at 6 months (n¼ 2), those who continued in the
group clinic reached low disease activity or remission by
8–13 months.
The clinics ran smoothly, with no noticeable waits
from arrival for the patients to complete the individual
diagnostic/treatment questionnaires and HAQ.
Logistically, it was sometimes difficult for the main
group clinic lead to complete a DAS28 score on each
participant; therefore, this could be delegated to the
pharmacy practitioner, rheumatology nurse or trainees,
depending on the skill mix available on the day. Patients
in the pilots were given the choice of having a serial ob-
served consultation (as recommended in the Kaiser
group models), but all groups preferred to raise issues
in an initial brain-storming session so that they could
be discussed with the group. The topics discussed
included the following: aetiology of RA, fatigue, flares
(including triggers and management), OA, chronic wide-
spread pain, sleep disturbance, risk vs benefits of
NSAIDs/coxibs/CSs, exercise, disease-modifying ther-
apy (monotherapy and combination), biologic therapies,
impact on work and relationships. A number of chal-
lenges were identified and solutions created by the
groups (see Table 2). Feedback was very positive
(Table 4) across all domains, with no significant differen-
ces in satisfaction between the established group clinics
(2008–19) and usual care. Satisfaction was equally high
for the early pilots (from 2008) and EAGCs (2016–18;
data not shown). Even patients who had very severe
disease where biologic therapy was contraindicated
through infection risk benefitted from the peer support
provided by the group clinic.
Only 12 patients (0.4%) who completed a feedback
questionnaire from all the clinics said that they would
not come to further group clinics, and 4 (<0.2%) said
they would not recommend them to others. Therefore,
even patients who do not personally want to use the
model recognize its potential value to others.
Qualitative findings
The qualitative data analysis from the inflammatory ar-
thritis group clinics identified five main enabling themes
(efficiency, empathy, education, engagement and em-
powerment), which were linked to key indicators of pa-
tient satisfaction (see Table 5).
Discussion
Rheumatology group consultations can be engaging,
empowering and efficient; patients enjoy them and have
a sense of involvement in their care, and this study has
shown that key disease outcomes can be collected,
informing the quality of care delivered. This is achieved
by the group clinic model delivering a longer contact
time than the one-to-one clinics, thus encouraging more
active patient involvement, and has potential to replace
some one-to-one clinics. Although not all patients want
to try this initially, the present study suggests that a sin-
gle positive experience can lead to the majority of
patients both wanting to use this model of care again
and becoming advocates. Given that this group model
is a self-replenishing one, there has not been a drop-off
in attendance, commitment or enthusiasm over time.
This is an important feature to consider, because the
studies identified in the evidence review commissioned
by the National Institute for Health Research [25] pointed
TABLE 4 Patient evaluation of inflammatory arthritis group
clinic and usual care
Question: How
would you rate
the clinic for. . .
(numerical rating
0–10; where
05very poor,
105very good)
Group clinic
Median
(IQR) n52859a
(85% response)
Usual care
Median
(IQR) n5393
(60% response)
Listening to you 10 (10–10) 10 (10–10)
Explaining disease
and treatment
10 (9–10) 10 (9–10)
Looking at
joints/skin
10 (10–10) 10 (9–10)
Opportunity to
discuss
treatment options
10 (10–10) 10 (9–10)
Providing treatment 10 (10–10) 10 (8–10)
Access to MDT 10 (10–10) 10 (9–10)
aTotal of 3363 attendances; not all patients completed and
returned the feedback sheet or answered all questions on
it, but the response rate was higher than that for usual
clinic care, for a postal questionnaire.
IQR: interquartile range; MDT: multidisciplinary team.
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TABLE 5 Enabling themes and promoting factors
Enabling
theme
Details Impact on patient care and
satisfaction
Promoting factor and implications
for translation
Efficiency Reduced waiting times
More streamlining of
administration at
clinic
More effective use of
time; more patients
seen in a session
Referrals and follow-up
‘It’s very helpful, and if there’s anything
that you’re concerned about, it’s
easier than waiting for 6 months for an
appointment’
‘You are not waiting in a queue like be-
fore; you are straight in and can have
tea and a chat while you fill the forms
in and wait for the doctor to see you
and do your joints’
‘I think that having a group, obviously
more people get seen, which has to
be, you know, more effective really’
‘I always make sure the secretaries
follow up people who didn’t come and
ask whether they want to be seen in
the next group clinic’
Prioritization
Translation points:
Have buy-in from entire clinical and ad-
ministrative team and include them
in the design, implementation and
evaluation of the process
Personalization
Translation points:
Ensuring that there are effective ways of
recording events of and action points
from the session with individualized
follow-up
Empathy Shared problems
Shared understanding
Group support
‘We are all in the same boat’
‘The group understands that the pain
gets you down, and it makes me feel
better when I hear others describing
what I go through every day’
‘You generally have a little chat while
you’re having a cup of tea and can get
a little bit of advice about whatever is
worrying you’
Participation. Translation points:
Need to create sense of belonging and
camaraderie
Education Learning from health-
care professional
Learning from others
‘I would never know all that about dis-
ease, you know if you’re below 3, or
you’re below 2.5 you’re in
remission. . .. I’ve got a much better
understanding of how my disease
works’
‘I think questions get asked that you
might not ask yourself because you
might feel silly, so you get the answers
that you want’
Pedagogical approach. Translation
points:
Content matches need, make relevant,
provide examples and state what that
means to them
Participation. Translation points:
Collect questions before group
discussion
Have opportunity for patients to ask
questions of each other
Engagement Appropriate personal-
ity, benefits of a
trained educator
Individualization in a
group setting
Positive physical and
emotional
environment
‘I think Dr A is very approachable and
he’s got a very good manner and
draws people out’
‘Well he’s very good in that he talks to
the group, but also he acknowledges
that you’re an individual’
‘You can go to the other room and get
your injection while he is seeing other
patients’
‘You can have a laugh, and it’s more re-
laxed, and you probably get a bit more
out of this than you do from a one to
one’
Personality/pedagogic approach.
Translation points:
Ensure that the right people are leading
the session, whio have passion, an
interest in teaching and skill
Personalization. Translation points:
The ability to differentiate in a multi-need
group
Prioritization. Translation points:
Need appropriate premises for delivery
and training in facilitation skills for
participating clinical staff
Empowerment Agency, autonomy and
advocacy
Focus on personal
impact
Promoting behavioural
change and physical
well-being
‘I just asked if I could have an
injection. . .. I got one, no problem at
all, and I went home feeling on top of
the world. You feel like you have some
control over your care!’
‘It’s made me realize I am not that badly
off but need to take more control so
not to get worse’
‘I have learnt tips on how to manage my
condition better, like doing regular ex-
ercise will improve my joints and make
me less tired’
Personalization. Translation points:
Ensure that the session is made relevant
to individual need: specific treatment
or advice is available, general topics
can be individualized (e.g. use exam-
ples from the patients, use names and
focus on how knowing this is important
and doing this will improve health
outcomes)
Participation/pedagogic approach.
Translation points:
Opportunity for both clinician and peer
advice and support is most impactful;
one validates the other
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to a reduction of these, particularly in cohort-based clin-
ics, whereby the group clinics studied here have shown
that the opposite can be true. Mean attendance at the
mixed group clinic increased from 15 to 23. Although
most would assume that patient experience would dete-
riorate when >15 attend, this study provides direct evi-
dence that this is not the case. Indeed, on the rare
occasions when numbers were low, there was less dis-
cussion. This is a highly counter-intuitive finding, which
can inform and change practice. Bigger group clinics
can deliver a better experience, as long as the space
and staff provision are right, whilst providing greater
efficiency.
As can be seen from the qualitative findings, five en-
abling themes (efficiency, empathy, education, engage-
ment and empowerment) appear to be present in
successful clinics, promoting high levels of acceptability
and sustainability with this patient population. In concert
with this, five promoting factors have been articulated to
help put these themes into practice and can broadly be
categorized into prioritization, personalization, participa-
tion, personality and pedagogical approach.
It is important to provide information ahead of the
patient’s first attendance at a group clinic regarding why
they have been chosen to attend, the format and what
they can do to prepare so that they can get the best out
of the clinic and also manage expectations. The way in
which these clinics are organized promotes a prompt
start, engaging patients immediately on arrival. They af-
ford the opportunity to embed quality/outcome data col-
lection, ensuring evidence-based practice. Education
addresses variability, invisibility and makes sense of
what is happening. This should ideally include multiple
modalities to reinforce learning (e.g. educational poster,
Supplementary Fig. S1, available at Rheumatology
Advances in Practice online). Moreover, group consulta-
tions provide one solution to allow delivery of an annual
review clinic within constrained resources and to ac-
commodate patients needing monthly review for tight
control. Finally, the model is flexible enough to facilitate
urgent review for flares or the addition of recently diag-
nosed patients without the inconvenience for others of
an overrunning clinic. This model can be adapted to
seeing emergencies; for example, as a drop-in clinic to
see patients in primary care at the weekend, or at other
times when demand outstrips supply. The total clinic du-
ration (90–120 min) was very similar whether 8 or 32
patients attended, with the logistical limit on group clinic
size being the size of room available in interactive layout
(usually in the round), in addition to the time taken to
carry out joint counts. Carers were welcome to join, as
for a normal clinic, but this provided an additional op-
portunity for their questions and concerns also to be
heard and shared without prolonging the session.
There were some differences between the early group
clinics and later ones, which is unsurprising because this
was part of a co-design process. The main difference in
treatments was the increase in i.m. CS injections for the
established clinics, compared with pilots. There are
several possible explanations for this. The later clinics in-
cluded the calculation of the DAS28 score; categorization
of disease activity as remission, low, moderate or high;
articulation of a treatment target (to achieve remission or
low disease activity); multi-disciplinary input; and the
opportunity to have an i.m. CS injection during the group
session, rather than having to wait and stay on after-
wards. All of these differences could have increased the
proportion of patients choosing to have i.m. CS injection,
but as observed in the TICORA study [5], the important
observation is probably that more CS injections were
given to those with active disease, whatever the element
of the care package responsible for this change. A major
change in the group clinic model was prompted by the
qualitative research as it became clear that patients
wanted more education from other team members; there-
fore, a process to incorporate other team members be-
gan. This process was facilitated by the establishment of
the early arthritis clinic, with two additional consultants
and several other multi-professional team members be-
coming actively involved, as the culture of the department
became much more oriented to group clinic care.
The key strengths of this study are that it is large,
long-term, covers multiple settings, clinicians and
centres and uses a mixed methods approach. There are
some important limitations to what was a pilot service
innovation, extended with agreement of the local health-
care commissioners. First, this was not a randomized
controlled trial, but a mixed methodology study collect-
ing observational data, which was appropriate to meet
the objectives stated. There was a direct comparison
of satisfaction with usual care using the same tool, but
without blinding, the results are potentially more suscep-
tible to bias. That said, blinding of patients is not
feasible for this type of package of care study, even in
randomized controlled trials, such as TICORA or
TICOPA. The proportion of patients achieving low dis-
ease activity or remission in the mixed early and chronic
disease group clinic is comparable to or better than reg-
istry data from two US cohorts, where routine practice
includes earlier use of anti-TNF therapy [26]. EAGC data
make it clear that the group approach delivers better
outcomes; the 6-month remission rate of 50%, and 89%
with low disease activity or remission, is equivalent to or
better than that achieved in other observational cohorts
or controlled trials. TICORA achieved 66% remission
after 18 months [5], and TACIT had 34% achieve remis-
sion at any time >12 months [27]. The only intervention
achieving a comparable remission rate of 55% by
6 months is tocilizumab [28], which has much higher
cost. For clarity, by the 6-month time point, no patients
in the EAGC had received biologic therapy, although
one patient did require biologic therapy to achieve re-
mission at 13 months.
Although the calculation of the DAS28 has been incor-
porated in the group clinic and is essential in agreeing a
treatment target with the patients, this is not collected
routinely in one-to-one clinics; therefore, the data from
those are not included, although as stated, patients
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were moved from monthly to annual review on reaching
remission (DAS28< 2.6) or a low disease activity state
(DAS28< 3.2; or fewer than three tender and swollen
joints in PsA). Equivalent satisfaction levels in both
mixed group clinics and the early arthritis model were
seen, compared with the survey of outpatients in the
same centres before the group clinics were initiated.
However, there was a ceiling effect for the questionnaire
used, which would limit the discrimination of any differ-
ences. Although satisfaction may change over time,
there is no specific reason to believe that the routine
service would have changed for the worse over the pe-
riod of the study, because these clinics were not ad-
versely affected by the group clinics. Indeed, the ability
to be able to add urgent extra patients to the group clin-
ics has tended to relieve pressure on the one-to-one
clinics, which have been less overbooked as a result,
meaning that this delivers benefits even to the patients
who do not opt in to this model. In the hospitals where
the service is established long term, 40% of follow-up
appointments are now delivered through group clinics.
There are two main strands of literature for compari-
son. The first is that of existing models of care for the
management of RA. This includes the predominant
model espoused by the EULAR [29], ACR [30] and NICE
NG100 [3]. These recommend annual review for stable
patients, with the implicit assumption of one-to-one
care, but there is little articulation of the resource impli-
cations. The UK National Audit Office report [31] sug-
gests that there are significant resource implications to
the implementation of a treatment-to-target strategy. By
increasing the proportion of patients treated within
3 months of onset from 10 to 20%, NAO estimated a
cost of £11 m (e12.3 m or $14.1 m, at 2018 exchange
rates) over 5 years, but potentially realizing overall sav-
ings to the economy of £31 m (e34.8 m or $39.8 m).
Proportionately larger savings could be made in in the
USA and other countries, especially if use of expensive
biologic therapies can be delayed or avoided.
The group clinic model is capable of delivering many
of the components of care that may explain the success
of the tight control strategy [5, 6], which was inspired by
diabetes care and also applies to other chronic dis-
eases. This includes a large and timely educational com-
ponent (to maximize early adherence to disease-
modifying therapy), regular i.m./IA CSs, rapid supported
escalation of disease-modifying drugs and the agree-
ment of a treatment target, shared with both the physi-
cian and the patient. Importantly, it provides patients
with a greater sense of empowerment and ownership of
the management of their disease by providing a social
constructivist approach to understanding their condition
and learning of a variety of methods of self-help gained
from the other patients, which feedback from patients
reported to be powerful and comforting (‘if others can
manage it, so can I’). The themes we articulate map
powerfully to ‘living precariously with rheumatoid arthri-
tis’, from a recent mega-ethnography describing 10 con-
ceptual categories [32]. Engagement and empowerment
especially address the control and lack of reciprocity
exerted by RA; education addresses the variability and
invisibility and makes sense of what is happening.
Groups help to reframe the situation and provide a posi-
tive experience [32]. Group clinics are also attractive in
providing more frequent outcome data than patient-
initiated follow-up [33] and a high level of consultant
contact compared with the nurse practitioner model
[34].
The second strand of literature relates to group clinics
in other specialities. As outlined above, the implementa-
tion of group clinics for RA differs significantly from the
models used by Kaiser, especially in generalizing the
problems covered in the clinic, rather than holding a
number of individual consultations within a group set-
ting. Indeed, there are at least three distinct models
used by Kaiser: the drop-in medical group appointment,
shared medical appointment and physical shared medi-
cal appointment; hence, comparisons are limited by dif-
fering methodologies. However, observational data for a
hypertension group intervention, a randomized con-
trolled trial for primary care patients with chronic condi-
tions and secondary care Veterans Affairs Medical
Center patients with diabetes and hypertension provide
evidence that these approaches can be efficient and
cost effective [11]. The National Institute for Health
Research-funded systematic review [25] showed that
most of the evidence on group clinics is related to dia-
betes care and practice in the USA. Having shown that
it is both feasible and sustainable to implement group
clinics in the UK, this justifies their more widespread use
in the UK and elsewhere. However, further studies
across a range of care settings, chronic conditions and
designs, with particular reference to efficacy and cost-
effectiveness outcomes, would be helpful.
With regard to implementation, overall, our findings
are consistent with previous research studies [14, 35],
emphasizing further the need for organizational buy-in,
group clinic champions, an investment in training and
development of clinical staff in teaching and facilitation
and an organization supportive of innovation [10].
Implementing and sustaining the group clinic model is
without doubt introducing ‘a new way of thinking, acting
or organizing’ [36] into the existing service, which is no
small task, and the challenges of both structural and
cultural change should not be underestimated. It is
important to win over both champions and decision-
makers to make it work. In relationship to cost implica-
tions, once up and running, group consultations have
been proved to be self-sustaining and cost-saving, al-
though this is somewhat determined by local factors
when considering economics in the roll out. This study
confirms that in the UK, similar efficiency of 200–300%
compared with usual care is achievable, as previously
shown in the USA [10]. The main strength of this team’s
implementation of group clinics was in its experience-
based co-design model approach, which held the model
to constant critique and refinements based on patient
and staff feedback and service need. This also enabled
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the team to identify factors that were unique to the
group clinic model. The open qualitative research design
also enabled the identification of the perceived benefits
and aspects of the delivery of care that were most im-
portant to the participants, rather than what the
researchers felt were important.
The qualitative findings could not emphasize more
strongly the importance of well-trained (in education and
facilitation), knowledgeable and personable clinical staff,
and this is supported substantially throughout the litera-
ture [10, 12, 14]. It was clear from the patient narratives
that it is important that they feel a sense of being
treated as an individual in the group setting. This was
achieved: before the clinic, in the personalized letter
inviting them to the clinic; on arrival, when the staff
knew their names and they were dealt with efficiently,
not waiting around by the reception window as in the
traditional clinics; by the consultant spending time with
each of them to talk about their concerns or ask ques-
tions; by use of names during the group education ses-
sion; and by the fact that the consultant remembered
their questions and referred back to them. Also, the fact
that other members of the group took time to contribute
to the discussion on their topic or provided tips for self-
management contributed to this sense of individualized
care despite the presence of many others in the room.
The degree of personalization was largely achieved by
the approach to facilitation of the educational compo-
nent of the clinic adopted. The consultant answered key
questions and addressed patients’ concerns but also
used a Socratic questioning approach to draw the
answers out of other patients. They were encouraged to
share their stories, give advice based on their own ex-
perience of managing their condition and encouraged to
think of the answers to some of the questions posed by
others. Some people were more reluctant to contribute
but enjoyed listening, and that is acceptable. It needs to
be noted, however, that this approach relies on the clini-
cian being skilled in facilitation, having high levels of
emotional literacy, the ability to monitor the engagement
levels of the individual members of the group and bing
able to identify genuine need in the busy and, at times,
demanding nature of the clinic. Those patients least
confident or able, perhaps through medical or linguistic
ability, to communicate and engage in a group setting
might be the ones who are most in need of additional
individualized care. There is also a need for clinicians to
balance explaining in lay language and reference to the
evidence base for the information being given. In our
study, patients commented on this; for example, the cli-
nician referred to the TICORA [5] study when explaining
why it is important to take your medication regularly,
and some patients felt this was over their heads, point-
ing to the need not to become too jargonistic, giving
only the key points of that study and what it means for
the patient. This provided a supportive, empathetic and
proactive environment for patients to have their experi-
ence validated and consider their options. The data
revealed that this, probably more than anything else,
was the key active ingredient of the success of the
group clinic.
Conclusion
This study addresses the issues highlighted by Ramdas
and Darzi [15] for any highly innovative service delivery
to become standard. First, it is a large mixed methods
study showing high patient satisfaction and 39% of
patients achieving low disease activity or remission in
heterogeneous and 89% in homogeneous EAGCs (50%
remission). With a current mean clinic size of 23 patients
and 40% of the Rheumatology outpatient delivery work-
load for the two original hospitals, the key findings of
this study are that group clinics are a sustainable, feasi-
ble, engaging, empowering and efficient method for
both monthly review of early active disease and annual
review of stable disease.
Second, by methodical iterative development using a
co-design approach with patients, clinical staff and key
stakeholders, enabling themes, which indicate patient
satisfaction and acceptability, have been used to inform
service improvement. Third, the study has also identified
barriers to success, established promoting factors, dem-
onstrated cost efficiencies and provided sustainability
metrics, which support the rolling out of the group clinic
model. We believe that this approach can help to allevi-
ate some of the burden of an overstretched and over-
stressed health-care system in the UK. Finally,
recommendations for clinical staff development in rela-
tionship to teaching and facilitation have been made,
firmly grounded in the feedback from the group clinic
patients. The patients have already made their satisfac-
tion with their involvement in the co-design and their
positive view of the model very clear.
There is already considerable interest in this model of
care, including high-profile editorials [8, 15] and a recent
review article exploring a systems approach to imple-
mentation [10]. This paper provides the data to underpin
this. Serious consideration is warranted to the applica-
tion of this model with inflammatory arthritis and a range
of other chronic diseases more widely across primary
and secondary care settings in the UK and elsewhere.
Clinicians, managers and health-care commissioners
who wish to implement this model of care should get in
touch with the corresponding author, who will connect
them with an appropriate local mentor or trainer,
depending on the setting and conditions proposed.
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